NEW YORK, Sept. 17 – Syrrx has received an exclusive license from the Scripps Research Institute to develop and commercialize XtalView, a software package for manipulating x-ray crystallography data of proteins, the company said Monday.
Originally written in 1991 by Duncan McRee, a former Scripps researcher who now serves as director of crystallography at San Diego-based Syrrx, the XtalView software performs semi-automated fitting, electron density mapping, phase determination, heavy atom refinement, and other computations on x-ray data, the company said.
The licensing agreement with Scripps, also based in San Diego, allows Syrrx to exclusively market, distribute, and further develop XtalView for at least five years. The company plans to use the software internally in its high-throughput protein structure determination efforts, as well as seek out customers who wish to sub-license the technology.
"XtalView has become an important part of Syrrx's high-throughput structure determination process and supports our drug discovery efforts," Wendell Wierenga, CEO of Syrrx, said in a statement. "Securing the rights to XtalView further strengthens the company's technology platform and expands our business opportunities."
In January, Syrrx entered into a five-year agreement with the Genomics Institute of the Novartis Research Foundation to exclusively license tools for cloning, protein expression, protein purification, and protein crystallization. In return, Syrrx allowed the institute to take a minority equity position in Syrrx and a seat on the company’s board of directors.